Thrombosis news, opinions and education

Arrhythmia/EP

Dabigatran 110 mg similar in benefit to 150 mg in weighted analysis

1 COMMENT - Jun 12, 2013 15:45 EDT

European, Canadian, and Australian regulators all approved both the 110-mg and 150-mg doses studied in the RE-LY trial, while the FDA approved only the higher dose. A new analysis is once again calling this decision into question.

Hamilton, ON - Reigniting a smoldering debate, a new analysis based largely on data from the RE-LY trial has found similar overall benefits to the higher and lower doses of dabigatran (Pradaxa, Boehringer Ingelheim) studied in that trial [1].
Read full article »

News

NIH says ATP 4, JNC 8 guidance out "in a matter of months" (with a twist)

Jun 19, 2013 14:15 EDT

Thrombosis

EMA committee concludes diclofenac poses similar risks as COX-2 inhibitors

Jun 14, 2013 14:45 EDT

MediaPulse

Yaz, Yasmin BCPs linked to 23 deaths in Canada

Jun 13, 2013 16:50 EDT

Thrombosis

Oversized 2-mg warfarin tablets recalled

Jun 13, 2013 10:30 EDT

Arrhythmia/EP

Severe sleep apnea may almost double risk of sudden cardiac death

Jun 12, 2013 17:00 EDT

Thrombosis

Aspirin unneeded with anticoagulation/clopidogrel after MI, PCI in AF

Jun 6, 2013 17:00 EDT

From the blogsView all »

Clotblog with Dr Samuel Goldhaber

Addressing isolation to counter terrorism

Jun 13, 2013 13:35 EDT

Editorial programs

Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team

View all »

Life and times of leading cardiologists. Guest: Richard Schatz

Jun 3, 2013 09:45 EDT

Healthcare reform and cardiology: An even-keeled update

May 2, 2013 08:45 EDT

Breaking embargo: PREVAIL and how we publish data from clinical trials

Apr 12, 2013 16:33 EDT

View all »Collections

heartwire collections groups our most compelling cardiology news coverage and editorial content by popular themes. Find everything on a single topic, in one place, with one click.

Antiplatelet up-and-comers

The quest for ever-more effective drugs to decrease platelet aggregation and reduce the...

Aspirin and primary prevention

Long considered an essential agent for primary cardiovascular disease prevention...

Dabigatran: A chronology

The presentation of the RE-LY results at the 2009 ESC meeting, showing that dabigatran...

Clopidogrel and PPIs

Proton-pump inhibitors have been prescribed to reduce the gastrointestinal risks of...

New warfarin competitors

For six decades, warfarin cemented its reputation as the world's most effective...

What's New